Genius Group to Host Investors Summit End of Feb.
Genius Group Limited (NYSE: GNS) announced today its sponsorship of and attendance at two major institutional investor summits in February.Genius Group is a proud sponsor of the Digital Assets Institutional Investor Summit taking place in Hong Kong on February 18, as a part of Consensus, Hong Kong 2025 organized by CoinDesk. The Company will be discussing with Asian institutional investors and funds the rise of Bitcoin Treasury Companies as an avenue to institutional exposure to Bitcoin.Genius Group is also a proud sponsor of Bitcoin Investor Week in New York from February 24-28, hosted by investor and entrepreneur Anthony Pompliano and featuring over 40 leading advocates of Bitcoin, including Senator Cynthia Lummis, Vivek Ramaswamy, Cathie Wood, Mike Novogratz, Anthony Scaramucci, with a focus on institutional Bitcoin adoption, corporate Bitcoin Treasuries, and the evolving role of Bitcoin in global finance.Genius Group CEO Roger Hamilton, said "Genius Group is currently the only Asian Bitcoin Treasury Company listed on a major US stock exchange. We have seen increasing interest from international investors in the combination of international Bitcoin exposure with zero capital gains tax together with the liquidity of the U.S. financial markets."GNS shares closed Thursday at 49 cents.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


